Advertisement

The Food and Drug Administration’s Fast Track Designation: Observations from the Initial Two Years of this Designation

  • David M. Cocchetto
Article

Abstract

A new moniker for investigational drugs was introduced in the Food and Drug Administration Modernization Act (FDAMA), which became law in November 1997. This moniker, the “fast track designation, “ is intended to offer a means for sponsors to propose, and FDA to officially recognize, that a specific investigational drug has demonstrated the potential to address an unmet medical need in the treatment of a serious or life-threatening condition. Such recognition is intended to facilitate development and expedite review of regulatory applications for fast track products (1). The purpose of this manuscript is to describe the fast track program. Information will be presented on the criteria to earn the fast track designation, benefits and challenges of the designation, and lessons learned from experiences reported in the public domain in the first two years that this designation has been available.

Key Words

Fast track designation FDA FDAMA 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Food and Drug Administration. Guidance for Industry. Fast track drug development programs-designation, development, and application review. Rockville, MD: Food and Drug Administration; September 1998.Google Scholar
  2. 2.
    21 CFR 312.81(a).Google Scholar
  3. 3.
    Food and Drug Administration. Investigational New Drug, Antibiotic, and Biological Drug Product Regulations; Procedures for Drugs Intended to Treat Life-Threatening and Severely Debilitating 111-nesses. Interim rule. Federal Register. October 21, 1988;53:41516–41524.Google Scholar
  4. 4.
    Food and Drug Administration. Investigational New Drug, Antibiotic, and Biological Drug Product Regulations; Treatment Use and Sale. Federal Register. May 22, 1987;52:19466–19477.Google Scholar
  5. 5.
    FDA expects to grant 90% of 60 fast track requests received annually. F-D-C Reports: The Pink Sheet. October 26, 1998; p 6.Google Scholar
  6. 6.
    Goldman B. Fast track. Presentation at the Annual Conference of the Regulatory Affairs Professionals Society, October 3-6, 1999, Washington, DC.Google Scholar
  7. 7.
    Food and Drug Administration. Center for Drug Evaluation and Research. Manual of Policies and Procedures (MAPP) 6020.3. Priority Review Policy. Rockville, MD: Food and Drug Administration; April 22, 1996. and Food and Drug Administration. Center for Biologics Evaluation and Review. Manual of Standard Operating Procedures and Policies (SOPP) 8405. Complete Review and Issuance of Action Letters. Rockville, MD: Food and Drug Administration; May 1, 1998.Google Scholar
  8. 8.
    21 CFR 314.50(d)(1)(iv).Google Scholar
  9. 9.
    Glaxo Wellcome Ziagen. F-D-C Reports: The Pink Sheet. June 29, 1998; p 32.Google Scholar
  10. 10.
    Gilead Sciences adefovir dipivoxil. F-D-C Reports: The Pink Sheet. July 5, 1999; p 32.Google Scholar
  11. 11.
    BioMarin will file 1999 BLA based on 10-patient clinical package. F-D-C Reports: The Pink Sheet. June 28, 1999; pp 25–26.Google Scholar
  12. 12.
    BioMarin’s MPS-1 filing delayed. Scrip. November 22, 1999.Google Scholar
  13. 13.
    Ilex/Lilly development agreement grows out of CRO contract for cancer drug. F-D-C Reports: The Pink Sheet. March 1, 1999; p 31.Google Scholar
  14. 14.
    Campath filed in the US. Scrip. January 4, 2000.Google Scholar
  15. 15.
    Vertex/Glaxo Wellcome Agenerase. F-D-C Reports: The Pink Sheet. October 19, 1998; p 32.Google Scholar
  16. 16.
    Matrix IntraDose. F-D-C Reports: The Pink Sheet. May 17, 1999; p 28.Google Scholar
  17. 17.
    US FDA grants Matrix’s IntraDose fast track status. Scrip. June 1, 1999.Google Scholar
  18. 18.
    Interneuron’s CerAxon for stroke to be fast-tracked. Scrip. April 6, 1998.Google Scholar
  19. 19.
    Cubist. F-D-C Reports: The Pink Sheet. January 18, 1999; p 28.Google Scholar
  20. 20.
    Genentech’s Herceptin “fast-track” review aided by rolling BLA. F-D-C Reports: The Pink Sheet. July 20, 1998; p 9.Google Scholar
  21. 21.
    Immunex Enbrel. F-D-C Reports: The Pink Sheet. August 10, 1998.Google Scholar
  22. 22.
    Cell Pathways Aptosyn. F-D-C Reports: The Pink Sheet. August 30, 1999; p 33.Google Scholar
  23. 23.
    Positive results in SLE from Genelabs. Scrip. September 24, 1999.Google Scholar
  24. 24.
    Genelabs GL701 lupus NDA will be complete in second half of 2000. F-D-C Reports: The Pink Sheet. November 29, 1999; pp 23–24.Google Scholar
  25. 25.
    Glaxo/Vertex’s protease inhibitor gets fast-track status. Scrip. December 20, 1999.Google Scholar
  26. 26.
    Sugen’s new sponsor is P&U; $650 mil. deal supplants AstraZeneca. F-D-C Reports: The Pink Sheet. June 21, 1999; p 21.Google Scholar
  27. 27.
    Miravant’s macular degeneration drug to be fast-tracked. Scrip. July 8, 1998.Google Scholar
  28. 28.
    Shaman hopes move from biotechnology to botanicals can rekindle magic. F-D-C Reports: The Pink Sheet. February 8, 1999; p 18.Google Scholar
  29. 29.
    Trimeris T-1249. F-D-C Reports: The Pink Sheet. May 17, 1999; p 28.Google Scholar
  30. 30.
    Foscan receives orphan status for head and neck cancer. Scrip. November 17, 1999.Google Scholar
  31. 31.
    Genentech Herceptin approval meets patient group deadline. F-D-C Reports: The Pink Sheet. October 5, 1998; p 3.Google Scholar
  32. 32.
    Purdue takes $100 million option on Altarex Mabs. Scrip. May 17, 1999.Google Scholar
  33. 33.
    Synsorb’s product fast-tracked by FDA. Scrip. January 14, 2000.Google Scholar
  34. 34.
    Wyeth Lederle vaccines. F-D-C Reports: The Pink Sheet. June 7, 1999; p 32.Google Scholar
  35. 35.
    FDA public log of fast track designated indications needed-PhRMA. F-D-C Reports: The Pink Sheet. March 1, 1999; p 7.Google Scholar
  36. 36.
    Food and Drug Administration. New Drug, Antibiotic, and Biological Drug Product Regulations; Accelerated Approval. Final rule. Federal Register. December 11, 1992;57:58942–58960.Google Scholar

Copyright information

© Drug Information Association, Inc 2000

Authors and Affiliations

  • David M. Cocchetto
    • 1
  1. 1.Regulatory Affairs DepartmentGlaxo Wellcome Inc.Research Triangle ParkUSA

Personalised recommendations